anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Upper extremity functions are of great importance, especially activities of daily living. There are opinions that the impairment of the upper extremity in scleroderma is greater than that of the lower extremity and affects the functional status of individuals more. This activity limitation is related to many activities of daily living, including unsupported upper limb movements that lead to dyspnea and fatigue in patients with cardiopulmonary disease. Therefore, determining the strength, endurance and exercise capacity of the upper extremities is an important issue in scleroderma management. One of the tests that serves this purpose is the 6PBRT, which has been found to be valid and reliable in patients with chronic obstructive pulmonary disease and asthma.

It was planned as a non-interventional reliability study. The study will investigate the validity and reliability of 6PBRT in patients with scleroderma. In this context, a 1-hour rest break will be given after the first test. Dyspnea and fatigue will be assessed using the Borg scale and muscle oxygenation, heart rate and blood pressure will be recorded before and after 6PBRT. After the 1-hour rest period, the second trial of 6PBRT will be performed. The level of dyspnea and fatigue and initial values of heart rate will be checked before the second trial to ensure that patients are stable. All assessments will be performed by the same physiotherapist. In addition, participants will be assessed for respiratory muscle strength, upper limb muscle strength and muscle oxidation during the performance test.

The smallest sample size of the study was 40 subjects with a correlation coefficient of 0.95 between the two tests and 90% power at 95% confidence interval. 50 subjects are aimed to be recruited against a 20% drop-out risk. Shapiro-Wilk test and histogram plots will be used to check the normality of the data. Demographic and clinical characteristics of the participants will be reported using descriptive statistics. Two-way random effects and absolute agreement methods and intraclass correlation coefficient (ICC) will be used to assess test-retest reliability. Reliability strength will be interpreted as excellent for an ICC value \>0.90. The 95% Confidence Interval (95% CI) will be calculated to investigate measurement variability.
BACKGROUND: Hemifacial spasm (HFS) is a debilitating disease characterized by involuntary tonic and clonic contractions of muscles innervated by the facial nerve. Botulinum toxin A (BTX-A) is the first-line option and the most effective medical treatment for HFS. The objective of this study was to evaluate the effect of BTX-A therapy on the physical and mental health of HFS patients.
METHODS: Participants included 65 HFS patients and 65 matched healthy controls in the study. Cornell Medical Index (CMI) self-assessment questionnaire was used to detect the psychological health of all participants. Local injection of BTX-A was applied, and the Cohen hierarchical criteria were employed to stratify the degree of spasticity, further evaluating the efficacy of BTX-A before and two months after treatment in HFS patients. The HFS patients at two months post-treatment were re-evaluated by CMI self-assessment questionnaire, and the evaluated factors of these patients were compared with those of patients before treatment.
RESULTS: The scores of somatization, depression, anxiety, inadaptation, sensitivity, anger, tension, M-R, and total scores in the HFS group were significantly higher than those in the control group (all P<0.05). Two months post-treatment, among 65 HFS patients who received with BTX-A treatment, 42 (64.6%) were completely relieved, 16 (24.6%) were significantly relieved, 7 (10.8%) were partially relieved, and 0 (0%) cases were invalid, and the total effective rate was 89.2%. Two months after BTX-A treatment, the scores of somatization, tension, anxiety, depression, sensitivity, M-R and total scores of patients with HFS were lower than those before treatment (all P<0.05).
CONCLUSIONS: Patients with HFS are often accompanied by somatization, anger, inadaptation, sensitivity, anxiety, depression, and tension. BTX-A can not only alleviate the symptoms of HFS, but also improve the somatization, tension, anxiety, depression, and sensitivity.
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational combination of drugs to learn whether the combination of drugs works in treating a specific cancer. "Investigational" means that the combination of drugs is being studied. It also means that the FDA (the U.S. Food and Drug Administration) has not yet approved the combination of drugs for your type of cancer.

Each of the individual drugs, lenalidomide , subcutaneous bortezomib, and dexamethasone, are approved by the U.S. Food and Drug Administration (FDA). The combination has not been approved yet for multiple myeloma or any other type of cancer. Subcutaneous bortezomib is currently approved by the U.S. FDA for the treatment of patients with relapsed/refractory multiple myeloma. Lenalidomide is currently approved for use with dexamethasone for patients with multiple myeloma who have received at least one prior therapy and for the treatment of certain types of myelodysplastic syndrome (another form of cancer affecting the blood). Both Bortezomib and Lenalidomide kill tumor cells and help the body cells to fight cancer. Dexamethasone is commonly used, either alone, or in combination with other drugs, to treat multiple myeloma. Dexamethasone heps to reduce irritation and cell injury (inflammation).

In this research study, the investigators are looking to explore the drug combination of lenalidomide, subcutaneous bortezomib and dexamethasone to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma. This 3 drug regimen showed promising results in previous studies, however administration of intravenous bortezomib caused high levels of nerve injury (a condition involving the nerves of the upper and lower extremities associated with numbness, tingling and burning). In this study, the investigators are testing the hypothesis that subcutaneous administration of bortezomib will result in less nerve toxicity. Therefore, the combination of lenalidomide, dexamethasone and subcutaneous bortezomib may be better tolerated and may allow for a longer duration of therapy.
PURPOSE: The Cardiometabolic Index (CMI) is a novel marker of visceral obesity and dyslipidemia. Our study aimed to explore the association between CMI and kidney stones among US adults.
METHODS: This cross-sectional study was conducted among adults with complete records of CMI and kidney stones information from the 2011 to 2018 National Health and Nutrition Examination Survey (NHANES). Inverse probability treatment weighting (IPTW) was used to balance the baseline characteristics of the study population. The independent relationship between CMI and kidney stones was evaluated using IPTW-adjusted multivariate logistic regression, restricted cubic splines (RCS), and subgroup analysis.
RESULTS: A total of 9,177 participants, with an average CMI of 0.72 (0.99), were included in this study. The IPTW-adjusted logistic regression revealed that CMI was an independent risk factor for kidney stones. The adjusted odds ratio (OR) for kidney stones were 1.39 (95% CI: 1.24 - 1.56, P < 0.001) for the second CMI tertile and 1.31 (95% CI: 1.17 - 1.47, P < 0.001) for the third CMI tertile, compared with the first CMI tertile. A linear relationship between CMI levels and kidney stone risk was observed in the RCS analysis. Subgroup analysis showed that the association between CMI levels and kidney stone risk remained stable across groups.
CONCLUSIONS: A positive association between CMI level and the risk of kidney stones was observed among US adults in our study. Further large-scale prospective studies are needed to validate our findings.
<P>PROBLEM TO BE SOLVED: To orally administer a precursor of adenosine triphosphate as dietary supplements to increase the intracellular ATP concentration or to deal with reduction of energy availability resulting from strenuous physical activity, illness or trauma.  <P>SOLUTION: Pentose sugars are administered individually, or mixed into dry food or solution. Preferred pentose is ribose, used singly or with creatine, pyruvic acid, L-carnitine and/or vasodilating agents. Additionally, magnesium, electrolytes, fatty acids and hexose sugars can be used. The compositions and methods are especially beneficial to mammals having reduced energy availability or high energy demand.  <P>COPYRIGHT: (C)2010,JPO&INPIT
3-Palmitoylglycerin-(1)-phosphorylcholine (D-alpha-lyso-lecithin) of formula (I), is an immunological adjuvant which in sub-lytic doses produces a changes in interfacial surface activity of animal cell membranes Prepn. is by resolution of racemic palmitoylglycerin into its optical antipodes or by the reaction scheme: 3,4-isopropylidene-D-mannitol is converted to its 1,2,5,6-tetra-Bz deriv., from which acetone is split off by acid hydrolysis and the resulting 1,2,5,6-tetra-Bz-D-mannitol is treated with Pb tetraacetate to give 1,2-diBz-glyceraldehyde which on metal hydride reduction gives 1,2-diBz-glycerin. This is acylated to the 2-Bz-3-palmitoyl-glycerin after removal of one Bz group. Reaction of this cpd. successively with beta-Br-ethylphosphoric acid dichloride and NMe3 gives the 2=Bz deriv. of (I) from which the Bz group is removed by hydrogenolysis.
A composition comprises microspheres formed from a polymer which is biodegradable, biocompatible and insoluble in an aqueous solution, wherein the microspheres further include a therapeutic agent. The injectable composition is useful for the intraocular delivery of a pharmaceutical agent, preferably an intravitreal VEGF inhibitor, which provides controlled release of the agent for the treatment of an ocular disorder such as wet macular degeneration. The biodegradable and biocompatible polymer preferably comprises a polyhydroxyalkanoate (PHA) such as poly(3-hydroxyalkanoates), poly(4-hydroxyalkanoates) and copolymers containing a PHA. Preferably each alkanoate unit has from 4 to 16 carbon atoms, for example, polyhydroxyoutanoate, polyhydroxyoctanoate and polyhydroxyvalerate. Copolymers such as poly (3-hydroxybutyrate-co-3-hydroxyvalerate), poly(3-hydroxybutyrate-co-4-hydroxybutyrate) and poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) may also be employed. The microspheres are preferably uniform in shape and have an average particle size of 0.1 to 10 microns. A process for producing a biodegradable and biocompatible polyhydroxyalkanoate polymer microaphere containing a therapeutic agent and an aqueous product comprising the miccospheres and an aqueous solution are also provided.
PURPOSE: To obtain new tannins, having remarkably high inhibiting activities to lipases and high safety and useful for the prevention of obesity based on inhibition of digestion and absorption of oils and fats, prevention and prophylaxis of diseases caused by the lipases, deterioration of foods, etc., and malodor. CONSTITUTION: The tannins of the formula [(n) is an integer of >=2] are obtained by extracting a fruit (legume) or a leaf of Cassia mimosoides var. nomame Makino, preferably the fruit thereof with a ketonic solvent (e.g. acetone), extracting the resultant extract with ether, treating the obtained extract according to column chromatography and purifying the treated extract, etc. The tannins have 1020 number-average molecular weight and 1120 weight- average molecular weight and are a brown powder mainly comprising 4 monomers (preferably 3',4',7-trihydroxyflavan). The compound is capable of manifesting a light red color by a vanillin-hydrochloric acid method without detecting sugars by an anthrone-sulfuric acid method.
BACKGROUND: Multiple Sclerosis (MS) can present several neurological symptoms with a progression that often leads to loss of cognitive and physical abilities. Sexual dysfunctions are frequent, although underestimated, MS symptoms significantly affecting the quality of life of these patients. The primary objective of this study was to assess the effectiveness of VR rehabilitation in enhancing the quality of life in individuals with MS. The secondary objective aimed to investigate whether the improvement in quality of life would also lead to enhanced sexual satisfaction and sexual function.
MATERIALS AND METHODS: Patients diagnosed with relapsing-remitting and secondary progressive MS and attending from November 2018 to March 2020 the Rehabilitation Laboratory of IRCCS Neurolesi "Bonino Pulejo" in Messina, Italy were enrolled in this study. All patients were randomized into either the control group (CG: 35 patients) that received traditional cognitive rehabilitation (CR) or the experimental group (EG: 35) undergoing VR.
RESULTS: The EG showed substantial improvements in various aspects of Multiple Sclerosis Quality of Life (MSQOL) between T0 and T1. Sexual function significantly improved, along with sexual satisfaction. Conversely, the CG achieved significant changes only in overall quality of life. Pearson's correlations highlighted the positive associations between sexual function and satisfaction, as well as with physical and mental well-being, underscoring the importance of improving sexual function as a marker of overall health.
DISCUSSION: This study is meant as exploratory as it addresses a fundamental yet overlooked aspect of rehabilitation, i.e., sexual function and sexual satisfaction, which could potentially be enhanced through rehabilitation in a VR environment. Registration DOI number: DOI 10.17605/OSF.IO/NB4MJ.
FOSCAVIR should be used with caution in patients with abnormal renal function because reduced plasma clearance of foscarnet will result in elevated plasma levels (see CLINICAL PHARMACOLOGY). In addition, FOSCAVIR has the potential to further impair renal function (see WARNINGS). Safety and efficacy data for patients with baseline serum creatinine levels greater than 2.8 mg/dL or measured 24-hour creatinine clearances < 50 mL/min are limited.

Renal function must be monitored carefully at baseline and during induction and maintenance therapy with appropriate dose adjustments for FOSCAVIR as outlined below (see Dose Adjustment and PATIENT MONITORING). During FOSCAVIR therapy if creatinine clearance falls below the limits of the dosing nomograms (0.4 mL/min/kg), FOSCAVIR should be discontinued, the patient hydrated, and monitored daily until resolution of renal impairment is ensured.

FOSCAVIR is not recommended in patients undergoing hemodialysis because dosage guidelines have not been established.
Epilepsy surgery is an option for people with focal onset drug-resistant (DR) seizures but a delayed or incorrect diagnosis of epileptogenic zone (EZ) location limits its efficacy. Seizure semiological manifestations and their chronological appearance contain valuable information on the putative EZ location but their interpretation relies on extensive experience. The aim of our work is to support the localization of EZ in DR patients automatically analyzing the semiological description of seizures contained in video-EEG reports. Our sample is composed of 536 descriptions of seizures extracted from Electronic Medical Records of 122 patients. We devised numerical representations of anamnestic records and seizures descriptions, exploiting Natural Language Processing (NLP) techniques, and used them to feed Machine Learning (ML) models. We performed three binary classification tasks: localizing the EZ in the right or left hemisphere, temporal or extra-temporal, and frontal or posterior regions. Our computational pipeline reached performances above 70% in all tasks. These results show that NLP-based numerical representation combined with ML-based classification models may help in localizing the origin of the seizures relying only on seizures-related semiological text data alone. Accurate early recognition of EZ could enable a more appropriate patient management and a faster access to epilepsy surgery to potential candidates.
PURPOSE:To obtain a flurbiprofen-containing external preparation excellent in percutaneous absorbing property and pharmacodynamic effects of a medicine and simply usable by blending flurbiprofen and a lactic acid ester into a tacky base. CONSTITUTION:This external preparation contains flurbiprofen and a lactic acid ester in a tacky base containing a rubber-based elastomer, a tackiness- providing resin and a plasticizer. The rubber-based elastomer participates in long acting property of pharmacodynamic effects due to stable release of the tacky base and the medicine, and a styrene-butadiene-styrene block copolymer is preferably used in an amount of 30-60wt.% as the elastomer. A rosin resin is exemplified as the tackiness-providing resin and the rosin resin is blended in an amount of 30-60wt.%. The lactic acid ester is blended in an amount of 5-25wt.% as a plasticizer for softening a percutaneous absorption promoter and a tacky agent, and cetyl lactate is exemplified as the lactic acid ester. The flurbiprofen is included in an amount of 1-15wt.% and the plasticizer is included in an amount of 5-25wt.%. Flurbiprofen-containing external preparation is preferably used as a cataplasm by applying it as medicine-retaining layer on a support for cataplasm.
Depression is common in pregnancy and affects about 70% of women and, for many women, pregnancy can lead to the first episode of major depression. Complications of intrapartum depression include intrauterine growth restriction, preterm labor, low birthweight, gestational diabetes, preeclampsia, decreased prenatal follow-up and suicide. For this reason, the standard of care has been to screen for depression during pregnancy and treat this illness, reducing maternal and fetal morbidity. Unfortunately, many first-line pharmacological approaches, such as serotonin reuptake inhibitors, may cause fetal malformations, persistent pulmonary hypertension and withdrawal syndrome. Thus, a non-pharmacological approach, without risk of fetal complications, would be ideal. The investigators propose a photobiomodulation based approach that uses non-ionizing near-infrared light (IRL) to upregulate mitochondrial function (through modulation of cytochrome c oxidase activity), which in-turn increase neurosteroid production and modulates GABAA receptor activity, thus alleviating depression. The investigators will perform a pilot study using IRL for the treatment of intrapartum depression. While other trials have shown success using IRL for depression in non-pregnant patients, this will confirm that photobiomodulation can modulate mitochondrial function and mitigate depressive symptoms compared to untreated controls in pregnancy by using real-time app-based depression scoring system and neuroimaging.
This study aimed to evaluate the clinical utility of intravenous indocyanine green (ICG) in the context of robot-assisted cystectomy (RAC) through a systematic review and meta-analysis. The primary focus was to compare postoperative complications and perioperative outcomes between the ICG cohort and the non-ICG cohort. The primary outcome indicators were the incidence of ureteroenteric strictures and the number of strictures anastomoses. A comprehensive search was performed across multiple databases, including PubMed, Embase, the Cochrane Library, and Web of Science, to identify pertinent studies that evaluate the application of ICG in RAC. The analysis of dichotomous variables was performed using relative risk (RR), while weighted mean difference (WMD) was utilized for comprehensive assessment of continuous variables. A total of 4 studies encompassing 732 patients were included in the analysis, comprising 311 patients who received ICG and 421 patients who did not. The baseline characteristics were found to be comparable between the two cohorts. The meta-analysis indicated that the occurrence of 90-day severe complications was markedly lower in the ICG cohort versus the non-ICG cohort (RR = 0.63, 95% CI 0.44-0.90, P = 0.011). In addition, the length of ureteral resection was longer in the ICG cohort compared to the non-ICG cohort (WMD = 0.25, 95% CI 0.01-0.49, P = 0.039), with notably significant results for right-side procedures (WMD = 0.54, 95% CI 0.28-0.80, P < 0.001). Nevertheless, no substantial differences observed between the two cohorts regarding the occurrence of ureteroenteric stricture, numbers of strictures at anastomoses, operative time (OT), length of hospitalization (LOS), or lymph node positivity. Compared with the non-ICG cohort, the ICG cohort had comparable efficacy and was able to reduce the incidence of 90-day severe complications. The use of intravenous ICG showed promising clinical applicability during RAC; however, additional long-term studies are necessary to substantiate its effectiveness.
Group A patients received autologous NHPBSC therapy through jet nebulization, in addition to the standard care, while Group B (No investigational intervention arm) received only the UAE approved standard care. The primary endpoints were the safety and efficacy assessment, measured as Adverse Reactions (ARs) incidence \[according to World Health Organization - Uppsala Monitoring Centre (WHO-UMC) causality assessment system\], rate of mortality within 28-days, and the time to clinical improvement of 2 points on a seven-category ordinal scale or discharge from the Hospital, whichever came first. Immune response profile, acute-phase serum markers, and coagulation testing profile were evaluated as well, before treatment (baseline - Day 0), at Day 14, and Day 21 (in patients with early response, defined as 2 points of difference in the clinical critical treatment index within 7 days of treatment, the assessment will be performed at Day 7). The trial was approved by the institutional ADSCC Research Ethics Committees (REC), and the Emirates Institutional Review Board (IRB) for COVID-19 Research and the written informed consent was obtained from all patients or from the patient's legal representative if the patient was too unwell to provide consent. SENTAD-COVID Study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice (GCP) Guidelines of the International Conference on Harmonization (ICH). The authors were responsible for designing the trial and for compiling and analyzing the data.